Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-12-20 Major Shareholding Noti…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Samil Pharmaceutical. It details specific transactions (buys/sells) by directors and major shareholders, including their names, relationships to the company, and the number of shares changed. This falls under the category of Director's Dealing or Major Shareholding Notification. Given the focus on individual director/major shareholder transactions, 'DIRS' (Director's Dealing) is the most accurate classification.
2024-12-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서), which is a standard regulatory filing in South Korea (DART system) used to disclose insider trading or changes in shareholdings by directors and major shareholders. This corresponds to the 'Director's Dealing' category.
2024-12-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and purpose of holding (management influence) for major shareholders and special related parties of Samil Pharm. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-12-20 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from Samil Pharmaceutical regarding the setting of a record date and the closure of the shareholder register for the purpose of the 72nd Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal notification of a corporate action. Given it is a standard regulatory disclosure regarding shareholder rights and meeting preparation, it fits best under the RNS category.
2024-12-16 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Samil Pharmaceutical (삼일제약) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which is characteristic of an interim/quarterly financial report. It is not a mere announcement or certification, as it contains substantive financial data. 9M 2024
2024-11-14 Korean
대표이사(대표집행임원)변경(안내공시)
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the resignation of a co-CEO (Kim Sang-jin) and the transition to a single CEO structure (Heo Seung-beom) for Samil Pharmaceutical. It explicitly details the change in management, the reason for the change, and the effective date. This fits the definition of a Board/Management Information filing.
2024-09-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.